Oxford BioMedica plc Management and Board change

5 June 2013

Oxford, UK – 6 June 2013: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, announces that Dr Stuart Naylor will step down from the Board of Oxford BioMedica and as Chief Scientific Officer at the Company’s Annual General Meeting today.  In line with the evolution of the Company’s strategy, the role of Chief Scientific Officer has been replaced with the role of Chief Medical Officer and Dr Madhu Davies, who has previously worked as a consultant to Oxford BioMedica, will be appointed to this position as of 7 June 2013. 

Oxford BioMedica has evolved from being a primarily research-driven organisation into a more commercially-focused company with increasing emphasis on activities such as clinical development and manufacturing.  After 16 years with Oxford BioMedica, Stuart and the Board agree that the time is right for Stuart to seek to apply his skills and expertise to new challenges, and for Oxford BioMedica to apply alternative expertise to support the Company in its next phase of growth.

Dr Madhu Davies MB ChB DRCOG DGM MRCGP FFPM CSci MBA (Cantab) is a medically qualified physician with more than 25 years’ industry experience.  Previously, Dr Davies has been responsible for leading the strategic development and management of products from concept through to registration, launch and lifecycle management across multiple therapeutic areas.  Dr Davies has also implemented global clinical development programmes from Phase I to III, through to market and has a strong track record of clinical evaluation, product registration and medical marketing both in Europe and the USA. 

Nick Rodgers, Chairman of Oxford BioMedica, said: “Having joined as a specialist in cancer biology in 1997, Stuart has played a significant role in the diversification of our research pipeline into CNS and ophthalmology. We are grateful for Stuart’s long-standing contribution to Oxford BioMedica and wish him every success in the future.  I would like to welcome Madhu to the management team – as a clinical-stage biopharmaceutical company, Madhu’s role will be key to delivering future commercial success.”

There is no other information to be disclosed under Paragraph 9.6.13 R of the Listing Rules.